Atea Pharmaceuticals, Inc.
AVIRNext catalyst
Bemnifosbuvir-Ruzasvir
HEPATITIS C VIRUS CHRONIC INFECTION
Get an email about AVIR's next catalysts
Track Atea Pharmaceuticals (AVIR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 3 readout).See the timeline
3 upcoming, 0 past
AVIR Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.50 | FQ end Sep/2026 | Call: tbd
Bemnifosbuvir-Ruzasvir Phase 3 Est. Readout
Primary completion for Bemnifosbuvir-Ruzasvir trial (NCT07037277) in HEPATITIS C VIRUS CHRONIC INFECTION
SourcePhase 3 — Bemnifosbuvir
For Hepatitis C Virus. Atea Pharmaceuticals has completed patient enrollment in the Phase 3 C-FORWARD trial evaluating bemnifosbuvir and ruzasvir for hepatitis C virus treatment, with topline results expected around year-end 2026.
SourceHow AVIR's past catalysts played out
Market Overview
Stock performance and key metrics
Bemnifosbuvir (BEM)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)
Bemnifosbuvir-Ruzasvir
HEPATITIS C VIRUS CHRONIC INFECTION
Bemnifosbuvir-Ruzasvir (BEM/RZR)
HEPATITIS C VIRUS CHRONIC INFECTION
Bemnifosbuvir
Chronic Hepatitis C Virus
AT-527
Hepatitis C
Ruzasvir
Chronic Hepatitis C Virus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bemnifosbuvir (BEM) | Phase 3 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection) | - | - |
Bemnifosbuvir-Ruzasvir | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION | - | - |
Bemnifosbuvir-Ruzasvir (BEM/RZR) | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION | - | - |
Bemnifosbuvir | Phase 2 | Chronic Hepatitis C Virus | - | - |
AT-527 | Phase 2 | Hepatitis C | - | - |
Ruzasvir | Phase 2 | Chronic Hepatitis C Virus | - | - |
HEPATITIS C VIRUS CHRONIC INFECTION
2 drugs in this indication
Chronic Hepatitis C Virus
1 drug in this indication
Hepatitis C
1 drug in this indication
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Atea Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Atea Pharmaceuticals, Inc.'s (AVIR) pipeline across Phase 3, Phase 2. Its lead program is Bemnifosbuvir-Ruzasvir (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Atea Pharmaceuticals, Inc.'s next FDA catalyst?→
Atea Pharmaceuticals, Inc.'s (AVIR) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AVIR biotech catalysts?→
Add AVIR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Atea Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.